Jove
Visualize
Contact Us

Related Concept Videos

Testing a Claim about Mean: Known Population SD01:11

Testing a Claim about Mean: Known Population SD

3.2K
A complete procedure of testing the hypothesis about a population mean is explained here.
Estimating a population mean requires the samples to be distributed normally. The data should be collected from the randomly selected samples having no sampling bias. The sample size needed to be higher than 30, and most importantly, the population standard deviation should be already known.
In most realistic situations, the population standard deviation is often unknown, but in rare circumstances, when it...
3.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

3.9K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
3.9K
Testing a Claim about Standard Deviation01:19

Testing a Claim about Standard Deviation

2.9K
A complete procedure to test a claim about population standard deviation or population variance is explained here.
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
2.9K
Testing a Claim about Mean: Unknown Population SD01:21

Testing a Claim about Mean: Unknown Population SD

5.7K
A complete procedure of testing a hypothesis about a population mean when the population standard deviation is unknown is explained here.
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2.

Human vaccines & immunotherapeutics·2026
Same journal

Post-vaccination HPV prevalence, genotype distribution, and associated factors among vaccinated women in China: A cross-sectional study.

Human vaccines & immunotherapeutics·2026
Same journal

Economic and epidemiological burden of HPV-related diseases in the Czech Republic: A claims database analysis.

Human vaccines & immunotherapeutics·2026
Same journal

Shared clinical decision-making for vaccination: A view through the lens of mid-adult HPV vaccination.

Human vaccines & immunotherapeutics·2026
Same journal

Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.

Human vaccines & immunotherapeutics·2026
Same journal

Development of a theory-based provider-focused training to improve HPV vaccine recommendations for young adults.

Human vaccines & immunotherapeutics·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 26, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

Drafting eligible biotech and immunotherapy claims.

Shyh-Jen Wang1

  • 1Division of Experimental Surgery, Department of Surgery and Rehabilitation and Technical Aids Center, Taipei Veterans General Hospital; Institute of Hospital and Health Care Administration, National Yang-Ming University, Tiapei, Taiwan, Taiwan.

Human Vaccines & Immunotherapeutics
|April 18, 2019
PubMed
Summary
This summary is machine-generated.

Recent court decisions impact patent eligibility for innovations like biomarkers and diagnostics. This study offers a flowchart to navigate patent law, guiding inventors toward patentable subject matter by avoiding natural laws and abstract ideas.

Keywords:
CAFCPatent eligiblebiotechimmunotherapy

More Related Videos

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.5K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.2K

Related Experiment Videos

Last Updated: Jan 26, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.5K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

20.2K

Area of Science:

  • Biotechnology
  • Intellectual Property Law
  • Medical Diagnostics

Background:

  • Recent US Supreme Court and Court of Appeals for the Federal Circuit (CAFC) rulings have significantly altered patent eligibility standards.
  • Groundbreaking innovations in biomarkers, diagnostic methods, and personalized cancer immunotherapy face patent ineligibility challenges.
  • This evolving legal landscape necessitates clear guidelines for patent protection in life sciences.

Purpose of the Study:

  • To analyze CAFC patent eligibility cases and develop a decision-making flowchart.
  • To provide strategic guidance for securing patent protection for biotechnological innovations.
  • To address the impact of recent case law on diagnostic and immunotherapy patents.

Main Methods:

  • Retrospective analysis of all relevant CAFC patent eligibility decisions.
  • Development of a flowchart based on judicial precedents.
  • Identification of claim drafting strategies to overcome eligibility rejections.

Main Results:

  • Inventions must avoid categories of natural law, natural phenomena, or abstract ideas to be patent-eligible.
  • Strategies such as claiming non-natural cDNA, including cell growth steps, or using means clauses may enhance eligibility.
  • Claims with substantive limitations, excluding well-understood, routine, or conventional activities, are theoretically eligible but lack successful CAFC precedent.

Conclusions:

  • The developed flowchart serves as a practical guideline for assessing patent eligibility.
  • Inventors and legal professionals can utilize these guidelines to draft stronger patent claims.
  • Navigating patent eligibility requires careful consideration of judicial interpretations and strategic claim construction.